After Touching Record High, Is GlycoMimetics, Inc. (GLYC)’s Near-Term Analysis Positive?

February 15, 2018 - By Adrian Mccoy

Investors sentiment decreased to 1.08 in 2017 Q3. Its down 0.83, from 1.91 in 2017Q2. It dropped, as 13 investors sold GlycoMimetics, Inc. shares while 11 reduced holdings. 5 funds opened positions while 21 raised stakes. 28.80 million shares or 2.36% less from 29.49 million shares in 2017Q2 were reported.
Fmr Limited has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 1.48M shares. Parametric Portfolio Limited Liability accumulated 77,056 shares. 17,607 are owned by Endurant Capital Management Limited Partnership. Blackrock Inc reported 524,610 shares. Columbus Circle Invsts stated it has 0.05% in GlycoMimetics, Inc. (NASDAQ:GLYC). State Street Corporation has 25,600 shares. Wellington Gru Ltd Liability Partnership holds 0.01% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC) for 3.49M shares. Artal Gp reported 202,500 shares. Natl Bank Of Ny Mellon owns 93,769 shares. The Ontario – Canada-based Td Asset Mgmt has invested 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Utd Service Automobile Association reported 71,932 shares. Nationwide Fund Advisors stated it has 14,866 shares. Price T Rowe Inc Md accumulated 1.10M shares. Redmile Group Inc Lc accumulated 1.21M shares. Hudson Bay Cap L P holds 125,000 shares or 0.04% of its portfolio.

Since September 18, 2017, it had 0 insider buys, and 2 sales for $56,020 activity.

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) reached all time high today, Feb, 15 and still has $26.99 target or 6.00 % above today’s $25.46 share price. This indicates more upside for the $874.24M company. This technical setup was reported by Barchart.com. If the $26.99 PT is reached, the company will be worth $52.45 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 3.33% or $0.82 during the last trading session, reaching $25.46. About 499,834 shares traded. GlycoMimetics, Inc. (NASDAQ:GLYC) has risen 81.25% since February 15, 2017 and is uptrending. It has outperformed by 64.55% the S&P500.

Analysts await GlycoMimetics, Inc. (NASDAQ:GLYC) to report earnings on March, 7. They expect $-0.26 EPS, up 27.78 % or $0.10 from last year’s $-0.36 per share. After $-0.24 actual EPS reported by GlycoMimetics, Inc. for the previous quarter, Wall Street now forecasts 8.33 % negative EPS growth.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Among 5 analysts covering GlycoMimetics (NASDAQ:GLYC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GlycoMimetics had 16 analyst reports since August 10, 2015 according to SRatingsIntel. Jefferies maintained GlycoMimetics, Inc. (NASDAQ:GLYC) rating on Tuesday, September 12. Jefferies has “Buy” rating and $16.0 target. The stock has “Buy” rating by Jefferies on Tuesday, December 19. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, August 3. The stock has “Buy” rating by SunTrust on Tuesday, July 26. The firm has “Outperform” rating given on Monday, August 15 by Cowen & Co. The firm has “Buy” rating by Jefferies given on Friday, July 7. On Monday, June 5 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by SunTrust on Tuesday, October 3 with “Buy”. Roth Capital maintained GlycoMimetics, Inc. (NASDAQ:GLYC) rating on Thursday, February 8. Roth Capital has “Buy” rating and $35.0 target. The firm earned “Buy” rating on Tuesday, June 6 by Cowen & Co.

Another recent and important GlycoMimetics, Inc. (NASDAQ:GLYC) news was published by Businesswire.com which published an article titled: “GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup …” on February 08, 2018.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $874.24 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.